Evidence map›Paper›PMID 29416362›Full record

ArticleInfection and drug resistance2018

Enriched whole genome sequencing identified compensatory mutations in the RNA polymerase gene of rifampicin-resistant

Mallika Lavania, Itu Singh, Ravindra P Turankar, Anuj Kumar Gupta, Madhvi Ahuja, Vinay Pathak, Utpal Sengupta

Open access · goldAbstract read
In one paragraph

Article in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Molecular Surveillance of Antimicrobial Resistance ofInfection and drug resistance · 2022
    Article
  3. Molecular Characterization of Rifampicin-ResistantAntibiotics (Basel, Switzerland) · 2021
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Mallika LavaniaStanley Browne Laboratory, The Leprosy Mission Trust India, TLM Community Hospital Nand Nagari.
Itu SinghStanley Browne Laboratory, The Leprosy Mission Trust India, TLM Community Hospital Nand Nagari.
Ravindra P TurankarStanley Browne Laboratory, The Leprosy Mission Trust India, TLM Community Hospital Nand Nagari.
Anuj Kumar GuptaAgilent Technologies India Pvt Ltd, Jasola District Centre, New Delhi, India.
Madhvi AhujaStanley Browne Laboratory, The Leprosy Mission Trust India, TLM Community Hospital Nand Nagari.
Vinay PathakStanley Browne Laboratory, The Leprosy Mission Trust India, TLM Community Hospital Nand Nagari.
Utpal SenguptaStanley Browne Laboratory, The Leprosy Mission Trust India, TLM Community Hospital Nand Nagari.
The Leprosy Mission International · GBAgilent Technologies (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite more than three decades of multidrug therapy (MDT), leprosy remains a major public health issue in several endemic countries, including India. The emergence of drug resistance in

Indexed as

compensatory mutationsIndialeprosyMDTnext generation sequencingrelapsedrifampicin resistance

Identifiers

PMID29416362
PMCPMC5790067
OpenAlexW2787797007

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.